Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Travere Therapeutics's operating margin for the twelve months ending Jun 30, 2026 was -6.8%. For fiscal 2026 it was -12.8%, against -138.9% the year before. The highest annual figure on record is -12.8% in fiscal 2026.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | -12.8% | +126.1 |
| FY2025 | Dec 31, 2024 | -138.9% | +128.4 |
| FY2024 | Dec 31, 2023 | -267.2% | +24.9 |
| FY2023 | Dec 31, 2022 | -292.2% | −140.9 |
| FY2022 | Dec 31, 2021 | -151.3% | −62.4 |
| FY2021 | Dec 31, 2020 | -88.8% | −10.5 |
| FY2020 | Dec 31, 2019 | -78.3% | −29.6 |
| FY2019 | Dec 31, 2018 | -48.7% | −14.0 |
| FY2018 | Dec 31, 2017 | -34.7% | +8.9 |
| FY2017 | Dec 31, 2016 | -43.6% | +7.2 |
| FY2016 | Dec 31, 2015 | -50.8% | +232.2 |
| FY2015 | Dec 31, 2014 | -283.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | 2.3% | +13.4 |
| Q1 FY2027 | Mar 31, 2026 | -29.0% | +23.2 |
| Q4 FY2026 | Dec 31, 2025 | -25.0% | +56.2 |
| Q3 FY2026 | Sep 30, 2025 | 15.1% | +104.4 |
| Q2 FY2026 | Jun 30, 2025 | -11.1% | +114.1 |
| Q1 FY2026 | Mar 31, 2025 | -52.2% | +284.3 |
| Q4 FY2025 | Dec 31, 2024 | -81.2% | +127.9 |
| Q3 FY2025 | Sep 30, 2024 | -89.3% | +160.3 |
| Q2 FY2025 | Jun 30, 2024 | -125.1% | +197.8 |
| Q1 FY2025 | Mar 31, 2024 | -336.5% | −21.3 |
| Q4 FY2024 | Dec 31, 2023 | -209.1% | +86.4 |
| Q3 FY2024 | Sep 30, 2023 | -249.6% | +44.6 |
| Q2 FY2024 | Jun 30, 2023 | -322.9% | −48.6 |
| Q1 FY2024 | Mar 31, 2023 | -315.2% | −7.8 |
| Q4 FY2023 | Dec 31, 2022 | -295.5% | −147.3 |
| Q3 FY2023 | Sep 30, 2022 | -294.2% | −247.7 |
| Q2 FY2023 | Jun 30, 2022 | -274.2% | −209.6 |
| Q1 FY2023 | Mar 31, 2022 | -307.5% | −207.2 |
| Q4 FY2022 | Dec 31, 2021 | -148.2% | +84.3 |
| Q3 FY2022 | Sep 30, 2021 | -46.5% | −8.5 |
| Q2 FY2022 | Jun 30, 2021 | -64.7% | −16.9 |
| Q1 FY2022 | Mar 31, 2021 | -100.3% | −68.8 |
| Q4 FY2021 | Dec 31, 2020 | -232.5% | −172.2 |
| Q3 FY2021 | Sep 30, 2020 | -38.0% | +39.6 |
| Q2 FY2021 | Jun 30, 2020 | -47.7% | +34.0 |
| Q1 FY2021 | Mar 31, 2020 | -31.5% | +65.1 |
| Q4 FY2020 | Dec 31, 2019 | -60.3% | −48.9 |
| Q3 FY2020 | Sep 30, 2019 | -77.6% | +9.8 |
| Q2 FY2020 | Jun 30, 2019 | -81.7% | −29.6 |
| Q1 FY2020 | Mar 31, 2019 | -96.6% | −50.0 |
| Q4 FY2019 | Dec 31, 2018 | -11.4% | +24.6 |
| Q3 FY2019 | Sep 30, 2018 | -87.4% | −61.1 |
| Q2 FY2019 | Jun 30, 2018 | -52.2% | −17.1 |
| Q1 FY2019 | Mar 31, 2018 | -46.6% | −3.8 |
| Q4 FY2018 | Dec 31, 2017 | -36.0% | +12.8 |
| Q3 FY2018 | Sep 30, 2017 | -26.3% | +33.7 |
| Q2 FY2018 | Jun 30, 2017 | -35.0% | – |
| Q1 FY2018 | Mar 31, 2017 | -42.9% | – |
| Q4 FY2017 | Dec 31, 2016 | -48.8% | – |
| Q3 FY2017 | Sep 30, 2016 | -60.0% | – |
See a number that looks wrong?